Rethinking Pharma Commercial Targeting with AI - with Philip Poulidis of ODAIA
<div>Commercial life‑sciences teams are facing a widening gap between strong brand strategy and fragmented real‑world execution, driven by misaligned workflows, static targeting, and an inability to act at the speed patients move through their therapeutic journeys. In this episode, Philip Poulidis, CEO and Co-founder of ODAIA, unpacks how AI can close that gap by connecting brand intent to real‑time execution, enabling teams to prioritize the right HCPs, orchestrate engagement, and measure impact through outcomes rather than activity metrics. He highlights …
Diese Folge wurde noch nicht transkribiert
Verwenden Sie STT.ai, um diese Episode mit AI zu transkribieren. Erhalten Sie präzisen Text mit Lautsprechererkennung, Zeitstempel und Export in mehreren Formaten.